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Abstract
Objective
To investigate the role of homocysteine in neuronal injury in HIV infection.
Methods
Using a cross-sectional design and archived samples, we compared concentrations of
plasma homocysteine and cerebrospinal fluid (CSF) neurofilament light protein (NFL), a
sensitive marker of neuronal injury, in 83 HIV-1-infected subjects without antiretroviral treat-
ment. We also analyzed plasma vitamin B12, serum folate, CSF, and plasma HIV RNA, the
immune activation marker neopterin in CSF and serum, and albumin ratio as a marker of
blood-brain barrier integrity. Twenty-two subjects provided a second sample median of 12.5
months after antiretroviral treatment initiation.
Results
A significant correlation was found between plasma homocysteine and CSF NFL concentra-
tions in untreated individuals (r = 0.52, p < 0.0001). As expected, there was a significant
inverse correlation between homocysteine and B12 (r = –0.41, p < 0.001) and folate (r = –0.40,
p = < 0.001) levels. In a multiple linear regression analysis homocysteine stood out as an inde-
pendent predictor of CSF NFL in HIV-1-infected individuals. The correlation of plasma homo-
cysteine and CSF NFL was also present in the group receiving antiretroviral therapy (r = 0.51,
p = 0.016).
Conclusion
A correlation between plasma homocysteine and axonal injury, as measured by CSF NFL,
was found in both untreated and treated HIV. While this study is not able to prove a causal
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Introduction
Prior to the discovery of effective antiretroviral therapy (ART), HIV-infected individuals had
about a 30% overall risk of developing HIV-related dementia (HAD) [1]. Although the picture
today is different, HIV diagnosis is to some extent still associated with HIV-associated neuro-
cognitive disorders (HAND). Symptoms of HAND are common in untreated HIV-positive
individuals and frequently reported by individuals on suppressive ART [2]. Recent studies
have noted increased levels of cerebrospinal fluid (CSF) neurofilament light protein (NFL) in
HIV-infected individuals, which is interpreted as a sign of ongoing neuronal injury. Elevated
levels of CSF NFL have not only been reported in individuals with neurological symptoms, but
also in some individuals with and without ART who are asymptomatic with regard to neuro-
logical symptoms [3,4].
Associations between elevated plasma homocysteine levels and cognitive impairment in
HIV-negative individuals have been the topic of many studies. Data suggest an association
between elevated levels of homocysteine and diseases of cognitive impairment such as Alzhei-
mer’s [5,6]. However, in the case of HIV-infected individuals, data on homocysteine levels in
the context of CNS injury and neurocognition are rare. The metabolism of homocysteine is
dependent on folate and vitamins B12 and B6, and therefore elevated levels of homocysteine are
an indicator of B12 and/or folate deficiency (Fig 1) [7]. This study investigates the possible asso-
ciation between homocysteine and neuronal injury in HIV-1-infected individuals.
Methods
Study design
A retrospective selection was made of samples collected in a prospective research program, as
previously described [8]. All samples were collected between 1999 and 2014 at the Department
of Infectious Diseases at Sahlgrenska University Hospital, Gothenburg, Sweden. Study partici-
pants were randomly chosen from individuals in the cohort who met the inclusion criteria, i.e.
untreated HIV-infection, over 18 years old, and no opportunistic CNS complications. Plasma
and CSF specimens from 83 HIV-infected untreated individuals were analyzed (Table 1).
Another plasma and CSF sample was obtained at a median of 12 months (range 10.8 to 27.1)
in 22 subjects on ART. Subjects without signs of neurological or cognitive impairment at clini-
cal examination were defined as neuroasymptomatic. Fifty-three of those had an asymptomatic
HIV-infection (Center for Disease Control and Prevention [CDC] classification A1-A3) [9].
Twenty-two patients fulfilled the criteria for AIDS (CDC classification C2-C3), 13 due to pneu-
mocystis pneumonia (PCP), four with tuberculosis, two with wasting syndrome, and one each
with Kaposi’s sarcoma, extracerebral lymphoma, and salmonella sepsis. Five patients had
symptomatic HIV-infections not categorized as AIDS (CDC classification B2-B3), all due to
oral candidiasis.
The untreated neuroasymptomatic individuals were divided into four subgroups according
to CD4+ T-cell count (T-cells/μL): CD4+> 350 (n = 21); CD4+ 200–349 (n = 20); CD4+ 50–
199 (n = 22); and CD4+< 50 (n = 17), based on earlier findings of higher CSF-NFL levels in
untreated subjects with lower CD4 cell counts [3]. Three additional patients with HAD were
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Fig 1. Homocysteine metabolism. Abbreviations: SAM, S-adenosyl-methionine; SAH, S-adenosyl-homocysteine; MTHF, methylenetetrahydrofolate;
THF, tetrahydrofolate.
doi:10.1371/journal.pone.0158973.g001
Table 1. Characteristics of Study Population.
Group N Age Gender Plasma HIV RNA CSF HIV RNA CD4+ T-cells (x10e6)
Median years (IQR) M/F Median Log10 (IQR) Median Log10 (IQR) Median (IQR)
Total (untreated, NA) 80 40.0 (33.0–49.0) 44/36 4.99 (4.32–5.47) 3.78 (3.10–4.32) 200 (60–360.5)
CD4 > 350 21 44.0 (31.0–52.0) 13/8 4.14 (3.60–4.76) 3.22 (2.29–3.92) 480 (400–670)
CD4 200–349 20 38.5 (31.75–43.75) 13/7 4.85 (4.32–5.35) 4.10 (3.37–4.47) 240 (218–275)
CD4 50–199 22 39.5 (34.25–52.5) 9/13 5.32 (4.75–5.64) 4.21 (3.81–4.75) 110 (75–148)
CD4 < 50 17 45.0 (38.0–47.0) 9/8 5.66 (5.16–5.91) 3.26 (2.23–3.75) 20 (10–30)
HAD 3 48.0 (42.0–52.5) 3/0 5.41 (5.18–5.87) 5.31 (4.81–5.36) 138 (99–184)
ART 22 43.5 (35.25–52.5) 10/12 < 1.7 < 1.7 395 (250–545)
Abbreviations: NA, neuroasymptomatic; HAD, HIV associated dementia; ART, Antiretroviral therapy
doi:10.1371/journal.pone.0158973.t001
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tested but not included in the statistical analyses. All predictors were selected based on earlier
findings of relevance to CNS HIV infection [3,10].
Laboratory assays
All samples were frozen to –70°C within an hour of sampling and stored until analysis. CSF
samples were centrifuged to remove cells and aliquoted before freezing. Levels of NFL in CSF
were determined using a commercial ELISA, according to the manufacturer’s instructions
(Uman Diagnostics, Umeå, Sweden). For neopterin a commercially available immunoassay
(BRAHMS, Hennigsdorf, Germany) was used. CD4+ count, CSF, and blood albumin levels
were analyzed according to local laboratory standards. CSF:blood albumin ratio was calculated
as a measure of blood-brain barrier dysfunction.
Plasma vitamin B12 and serum folate were quantified using an electrochemiluminescence
immunoassay on a cobas e analyzer (Roche, Penzberg, Germany). Total homocysteine was
determined in EDTA plasma by stable isotope dilution liquid chromatography tandem mass
spectrometry (LC-MS/MS) using a Quattro micro instrument (Waters Corporation, Milford,
MA, USA), essentially as described by Magera et al. [11]. Levels of HIV RNA, both in CSF and
plasma, were determined using the Roche Amplicor version 1.5, or Roche COBAS TaqMan
assay version 1 or 2 (Hoffman La-Roche, Basel, Switzerland)
Statistical analysis
Correlations were analyzed by Pearson correlation analysis. Paired T-test was used to compare
the treatment group before and during treatment. Differences between groups were analyzed
with ordinary one-way ANOVA and P values were adjusted for multiple comparisons using
the Tukey’s Range test. Predictors of log10 plasma homocysteine and CSF NFL were analyzed
by multiple linear regression analysis with forward selection. In the analyses CD4+ count, CSF:
blood albumin ratio, plasma and CSF HIV RNA, serum and CSF neopterin, CSF NFL, plasma
homocysteine, plasma vitamin B12, and serum folate were log transformed to reduce skewness.
P< 0.05 was considered significant.
All statistical tests were performed with SPSS version 21 (IBM SPSS Statistics, Armonk, NY,
USA) or Prism version 6.0 (Graphpad Software Inc., La Jolla, CA, USA).
Ethics approval and informed consent
The entire study and the procedure used to assure the anonymity of the data was approved by
the Research Ethics Committee of the University of Gothenburg, in accordance with the Hel-
sinki Declaration of 1975, as revised in 2000. All participants gave their informed consent in
writing. All patient information was anonymized prior to analysis by study Principal investiga-
tor (MG) at the Department of Infectious Diseases, at Sahlgrenska University Hospital.
Results
Descriptive statistics
Among the 80 untreated neuroasymptomatic subjects, 20 had moderate hyperhomocysteine-
mia (> 15 μmol/L). Twenty had elevated levels of CSF NFL, compared to age-dependent labo-
ratory norms. B12 levels were below 140 pmol/L in 2 subjects, and below 250 pmol/L in 32. One
individual had a high serum folate concentration. Of the three individuals with HAD, two had
hyperhomocysteinemia and two had CD4+ counts< 200. All three had very high levels of CSF
HIV RNA and CSF NFL.
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Group comparisons
Comparison of the subgroups of untreated neuroasymptomatic subjects showed a significant
difference in homocysteine levels between the groups (p = 0.0002). The group with CD4+
count< 50 had homocysteine levels significantly higher than the other groups (Fig 2a). Differ-
ences between groups were also detected in levels of CSF NFL (p = 0.0001). The CD4+< 50
group had significantly higher levels than the groups with CD4+> 350 and CD4+ 200–349.
The CD4+ 50–199 group had higher levels compared to the CD4+> 350 group (Fig 2b). No
significant difference between groups was found in plasma B12 or serum folate levels (Fig 2c
and 2d).
Predictors of CSF NFL and homocysteine
We found a significant correlation (r = 0.51, p< 0.0001) between the plasma level of homocys-
teine and CSF NFL (Fig 2e). As expected, there was also a significant inverse correlation of
homocysteine and B12 (r = –0.36, p = 0.0009), and of homocysteine and folate (r = –0.40,
p = 0.0003). Homocysteine was also found to correlate significantly to the CSF:blood albumin
ratio (r = 0.25, p = 0.023), CD4+ count (r = –0.41, p = 0.0002), age (r = 0.40, p = 0.0002), and
treatment with trimethoprim-sulfamethoxazole (r = 0.355, p = 0.001). Plasma homocysteine
Fig 2. A-F. Levels of homocysteine, NFL, vitamin B12, and folate. Correlations of homocysteine and CSFNFL.A-D: Levels of homocysteine, NFL,
vitamin B12, and folate in a cohort of HIV-infected individuals divided into groups. Neuroasymptomatic individuals are divided according to CD4+ T-Cell
levels. Individuals with HAD and those on ART are presented as individual groups. * Adjusted p values. E: Correlation of Log P homocysteine and Log
CSF NFL in 80 untreated, neuroasymptomatic HIV-infected individuals. F: Correlation of Log P homocysteine and Log CSF NFL in 22 neuroasymptomatic
HIV-infected individuals on ART. Abbreviations: P, plasma; HAD, HIV associated dementia; ART, antiretroviral therapy; CSF, cerebrospinal fluid; NFL,
neurofilament light protein.
doi:10.1371/journal.pone.0158973.g002
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correlated to serum neopterin (r = 0.34, p = 0.002), but no correlation was found between
homocysteine and CSF neopterin. No significant correlation was found between CSF NFL and
B12 concentrations. A weak correlation was found between serum folate and CSF NFL (r =
0.28, p = 0.012).
Using multiple linear regression analysis age, plasma vitamin B12, serum folate, plasma HIV
RNA, and treatment with trimethoprim-sulfamethoxazole were found to predict plasma
homocysteine; however, serum neopterin and CD4+ count did not (Table 2). Plasma homocys-
teine, CSF neopterin, age, plasma HIV RNA, and CD4+ count stood out as independent predic-
tors of CSF NFL, with adjusted estimates in the multivariate analysis. By contrast, CSF:blood
albumin ratio, CSF viral load, serum neopterin, plasma vitamin B12, and serum folate were not
found to be significant predictors (Table 3).
CSF NFL and homocysteine correlation after initiation of ART
The correlation of plasma homocysteine and CSF NFL was still present in the group on ART
(Fig 2f). No significant differences in levels of plasma homocysteine or CSF NFL were found in
the ART group before compared to during ART.
Table 2. Predicting Log P Homocysteine.
Univariable Multivariable
Predictor Std b (r) p Std badj p
Age 0.403 < 0.001 0.310 0.001
Log CD4 –0.411 < 0.001
Log P HIV RNA 0.395 < 0.001 0.262 0.008
Log S Neopterin 0.340 0.002
Log P B12 –0.363 0.001 –0.256 0.007
Log S Folate –0.401 < 0.001 –0.191 0.039
Trimethoprim 0.355 0.001 0.225 0.020
Univariable correlation (left columns) and multiple linear regression (right columns) determining predictors of log10 plasma homocysteine in 80 HIV-infected
neuroasymptomatic individuals without ART.
doi:10.1371/journal.pone.0158973.t002
Table 3. Predicting Log CSF NFL.
Univariable Multivariable
Predictor Std b (r) p Std badj p
Age 0.475 < 0.001 0.327 0.001
Log CD4 –0.469 < 0.001 –0.287 0.003
Log CSF HIV RNA 0.058 0.609
Log CSF Neopterin 0.379 0.001 0.271 0.002
Log CSF/P albumin ratio 0.267 0.016
Log P B12 -0.165 0.143
Log S Folate -0.284 0.012
Log P Homocysteine 0.507 <0.001 0.211 0.037
Univariable correlation (left columns) and multiple linear regression (right columns) determining predictors of log10 CSF NFL in 80 HIV-infected
neuroasymptomatic individuals without ART.
doi:10.1371/journal.pone.0158973.t003
Association between Plasma Homocysteine Levels and Neuronal Injury in HIV Infection
PLOS ONE | DOI:10.1371/journal.pone.0158973 July 21, 2016 6 / 9
Discussion
Our results show an independent correlation of plasma homocysteine and CSF NFL concentra-
tions in neuroasymptomatic HIV-infected individuals, both untreated and those on ART. To
the best of our knowledge, this is the first report that shows an association in any disease
between NFL, a sensitive biomarker of neuronal injury, and plasma homocysteine.
Earlier studies have shown the prevalence of hyperhomocysteinemia in untreated HIV-
infected individuals to be between 20% and 35% [12,13]. This is similar to our finding of 25%.
Homocysteine levels increase with B12 vitamin and folate deficiency and are also influenced by
renal function, age, and treatment with certain medications, e.g. trimethoprim. None of the
subjects in our study had impaired renal function, and retrospective analysis of medical records
showed that none were taking B vitamins. However, we discovered elevated levels of vitamin
B12 in plasma in 14 samples, suggesting the possibility of B12 vitamin supplementation that was
not recorded in patient files.
Trimethoprim treatment increased levels of homocysteine in a small number of healthy
men [14]. However, no changes in homocysteine were seen in HIV-positive individuals on pro-
phylactic doses of trimethoprim-sulfamethoxazole [15]. Seven individuals in our cohort
received prophylactic and 13 treatment doses of trimethoprim-sulfamethoxazole. The correla-
tion found between homocysteine and CD4+ cell count in the univariate analysis disappeared
in the multivariate analysis. This may in part be explained by trimethoprim-sulfamethoxazole
treatment of subjects with pneumocystis jiroveci pneumonia and low CD4+ cell count.
Elevated levels of CSF NFL are nearly always present in individuals with HAD [3,4], and
increased levels can already be found 1 to 2 years before the development of overt dementia
symptoms [8]. Consequently CSF NFL has been proposed as a predictive marker of HIV-asso-
ciated neurocognitive disease before clinical symptoms appear [4,8]. In untreated neuroasymp-
tomatic, HIV-infected individuals, markedly elevated CSF NFL levels signifying ongoing
axonal injury are mainly found in those with low CD4+ cell counts [3]. Although our findings
do not prove a causal link, they suggest homocysteine and functional B12/folate deficiency may
be involved in the pathogenesis of CNS neural injury in HIV infection. In agreement with ear-
lier findings, CSF NFL was higher in subjects with low CD4+ cells. CSF NFL also correlated
with age and CSF neopterin. Moreover, as expected, correlations existed between age, B12,
folate, and homocysteine.
HIV-infected individuals have increased levels of neopterin in CSF and serum as a result of
immune activation [10]. Earlier studies of HIV-negative individuals have found a correlation
between homocysteine and serum neopterin, implying an association between homocysteine
and immune activation [16]. It has been hypothesized that neopterin, through the influence on
folate metabolism, inhibits methionine synthase [17]. In addition, nitric oxide from activated
macrophages may also inhibit the enzyme [18]. Another proposed explanation of the role of
immune activation in hyperhomocysteinemia is through the oxidation of B12 and folate. This
could give rise to a functional deficiency that has the potential of both enhancing oxidative
stress and perturbing the methylation process [19]. However, we did not find serum neopterin
to be an independent predictor of homocysteine in multivariate analysis. In an earlier study of
individuals with dementia, treatment with B vitamins reduced the level of homocysteine but
did not influence neopterin concentrations [20].
The measurement of B12 is a poor marker of B12 deficiency, whereas homocysteine is more
sensitive [21]. This may partly explain the lack of correlation we found between CSF NFL and
plasma vitamin B12. The inhibition of crucial enzymes, or the lack of adequate forms of B12/
folate, may also explain disturbances in the homocysteine metabolism, even when there are suf-
ficient levels of B12 and folate. The homocysteine lowering effect of B vitamin treatment
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supports the presence of functional B12 and/or folate deficiency in the HIV-negative popula-
tion. The limited data available indicates that this is also the case in HIV-positive individuals
[22].
Significantly, the correlation between CSF NFL and plasma homocysteine remained present
in the group on ART. We found a correlation between homocysteine and HIV RNA levels in
serum in untreated HIV, but we did not find a significant change in homocysteine levels before
compared to after ART initiation.
Previous studies of the association of B vitamin levels and neurocognitive function in
untreated HIV-infected individuals have been inconclusive [23–25]. Impaired information
processing speed and visuospatial problem solving abilities have been reported in untreated,
neuroasymptomatic HIV-infected individuals with B12 deficiencies [23]. A small study
reported improvement of neuropathic symptoms in such individuals when given replacement
therapy [24].
There are several limitations to our pilot study: it is of retrospective design; the sample size
was limited; no HIV-negative control group was included; and neuropsychiatric testing was
not performed on all asymptomatic subjects.
Conclusion
We found a correlation between plasma homocysteine and axonal injury, as measured by CSF
NFL, in both untreated and treated individuals with HIV. While our study is unable to prove a
causal link, homocysteine and functional B12/folate deficiency appear to play a role in neural
injury in HIV-infected individuals that is worth exploring.
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